What Is MOTS-c? A Complete Guide to the Mitochondrial-Derived Peptide

MOTS-c occupies an unusual position in modern peptide research. Unlike almost every other research peptide, it isn't encoded by nuclear DNA — it's encoded within the mitochondrial genome itself, making it one of the few known peptides that originate inside mitochondria rather than being imported into them. This mitochondrial origin has driven substantial research interest across metabolic biology, exercise physiology, and aging research since its identification in 2015.

This guide covers what MOTS-c is, how it was discovered, how it functions mechanistically, and where it fits within the current research peptide landscape. For research groups selecting compounds for mitochondrial biology, metabolic research, or aging research designs, understanding MOTS-c's specific properties — and how they differ from nuclear-encoded research peptides — is essential to matching the compound to the research question.

Our MOTS-c research peptide is available at ≥99% HPLC purity with mass-spec-verified identity and batch-specific certificates of analysis. Every vial is supplied strictly for laboratory research use only. As of mid-2026, MOTS-c is investigational and not approved by any regulatory agency — the current Phase 2a trial (NCT07505745) represents the first significant human clinical investigation of the compound.

The Core Definition

MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA (the MT-RNR1 gene), functioning as a mitochondrial-derived peptide (MDP) that activates AMPK signaling and translocates to the nucleus under metabolic stress to regulate nuclear gene expression. The name is an acronym: Mitochondrial Open Reading Frame of the 12S rRNA-Type C.

The mitochondrial encoding is what makes MOTS-c scientifically distinctive. Virtually every other peptide in the research catalog — BPC-157, TB-500, Retatrutide, Tesamorelin — is encoded by nuclear DNA and either endogenous to specific tissues or synthetic. MOTS-c is different: its genetic origin lies within mitochondria themselves, in the 12S ribosomal RNA gene region. This positions the compound at the interface of mitochondrial biology, cellular energy sensing, and nuclear gene regulation in a way that no nuclear-encoded peptide can occupy.

Beyond the encoding origin, MOTS-c has three defining functional characteristics: it activates AMPK (the master energy-sensing kinase in mammalian cells) through an indirect pathway involving AICAR accumulation, it translocates from mitochondria to the nucleus under metabolic stress conditions, and its plasma concentration in humans and animals declines progressively with age. All three characteristics anchor its current research applications.

The Discovery History

MOTS-c was identified in 2015 by Changhan David Lee and colleagues in the Pinchas Cohen laboratory at the University of Southern California's Davis School of Gerontology — extending the small class of mitochondrial-derived peptides (MDPs) that began with humanin in 2001. The discovery emerged from systematic investigation of small open reading frames within mitochondrial DNA and their potential to encode functional peptides.

Why the discovery mattered

Before MOTS-c, mitochondria were primarily understood as bioenergetic organelles — the cell's power plants, producing ATP through oxidative phosphorylation. The discovery that mitochondrial DNA could encode signaling peptides that leave the mitochondrion and act on the broader cell represented a substantial expansion of what mitochondria are understood to do. MOTS-c specifically demonstrated that mitochondria communicate with the nucleus through peptide messengers — a mitochondrial-nuclear retrograde signaling pathway that has become an active research area.

The MDP family context

MOTS-c is one of a small class of mitochondrial-derived peptides (MDPs). Humanin was the first MDP identified, in 2001 by researchers investigating Alzheimer's disease. Additional MDPs have been characterized since, including the SHLPs (small humanin-like peptides). MOTS-c remains the most extensively studied MDP with systemic signaling activity, positioning it as the reference compound for research designs investigating mitochondrial-nuclear communication.

Research expansion after 2015

Since Lee's original 2015 characterization, published research on MOTS-c has expanded substantially across multiple domains. Peer-reviewed research is searchable through PubMed MOTS-c research. Notable recent work includes a 2023 review published in Frontiers in Endocrinology by Zheng, Wei, and Wang characterizing the compound's therapeutic exploitation potential, and a June 2025 study by Pham and colleagues at the Auckland Bioengineering Institute published in Frontiers in Physiology demonstrating MOTS-c restoration of mitochondrial respiration in type 2 diabetic hearts.

How MOTS-c Works: The AMPK Activation Mechanism

MOTS-c activates AMPK indirectly by disrupting the de novo purine synthesis pathway in the folate cycle, leading to AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) accumulation — AICAR is a well-established AMPK activator, and its accumulation triggers the downstream metabolic effects associated with MOTS-c. This indirect mechanism distinguishes MOTS-c from compounds that bind AMPK directly.

The AICAR pathway

The specific mechanism involves the folate cycle — the metabolic pathway responsible for one-carbon metabolism and nucleotide synthesis. MOTS-c interferes with de novo purine synthesis at a specific point that causes AICAR to accumulate. AICAR is an intermediate in the purine synthesis pathway, but it also functions as a potent AMP mimetic that activates AMPK. When AICAR accumulates due to MOTS-c interference with purine synthesis, AMPK activation follows.

Why AMPK activation matters

AMPK is the master energy-sensing kinase in mammalian cells. When activated, it shifts cellular substrate handling toward energy-generating pathways: increased glucose uptake, enhanced fatty acid oxidation, and improved mitochondrial biogenesis. AMPK activation is also central to the metabolic response to exercise, caloric restriction, and metformin — three of the most extensively studied longevity-related interventions. This is why MOTS-c is often described as an "exercise mimetic" — it activates the same energy-sensing kinase pathway that exercise activates through different upstream mechanisms.

Nuclear translocation

Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it directly regulates nuclear gene expression. This nuclear localization was demonstrated in Lee's original characterization and confirmed in subsequent research. The specific nuclear genes regulated by MOTS-c connect to metabolic adaptation, stress response, and cellular energy management — the same biological programs that AMPK activation supports. This dual mechanism (AMPK activation through AICAR + direct nuclear gene regulation) makes MOTS-c mechanistically unusual among research peptides.

For a deeper mechanism explanation with additional context on the AMPK signaling cascade, see How Do Mitochondrial Peptides Affect Metabolism?

Why Age-Related MOTS-c Decline Matters

Plasma MOTS-c concentrations decline progressively with age in humans and animals — a pattern that parallels the age-related decline of other bioactive peptides (NAD+, IGF-1, GHK-Cu) and forms the foundation of MOTS-c's role in aging research. The decline gives research designs a clear age-related hypothesis to investigate: aging causes MOTS-c scarcity, and restoring availability may address downstream mitochondrial and metabolic effects.

The age-related decline is documented in multiple published studies. Human plasma samples from older donors consistently show lower MOTS-c concentrations than samples from younger donors. Animal models show similar decline patterns. The decline correlates with the broader mitochondrial dysfunction that accompanies aging — decreased mitochondrial biogenesis, impaired oxidative phosphorylation efficiency, and reduced mitochondrial-nuclear communication.

Research implications

The age-related decline hypothesis has driven substantial aging research interest in MOTS-c. Mid-life administration in mouse models has been examined for effects on healthspan markers. Research designs investigating exercise adaptation in older populations have used MOTS-c to probe whether exogenous replenishment restores exercise-mimetic effects. The compound sits at the intersection of mitochondrial aging research and metabolic aging research, providing a research tool that addresses both simultaneously.

For deeper coverage of MOTS-c in aging research contexts, see Best Peptides for Anti-Aging Research: A Comparison Guide for Canadian Labs.

Current Clinical Research Status

MOTS-c is not FDA approved for any human therapeutic use — as of mid-2026, the compound is being investigated in a Phase 2a randomized, double-blind, placebo-controlled clinical trial (NCT07505745) in adults with prediabetes and overweight or obesity. This represents the first substantial human clinical investigation of MOTS-c itself, distinct from earlier trials of the CB4211 analog.

The Phase 2a prediabetes trial (NCT07505745)

The current Phase 2a trial is investigating MOTS-c in adults with prediabetes and overweight or obesity over a 16-week treatment period. The primary efficacy endpoint is change from baseline in OGTT-derived insulin sensitivity, measured by the Matsuda Index. Safety endpoints track treatment-emergent adverse events over the trial period. The trial design reflects MOTS-c's characterized effects on glucose metabolism and insulin sensitivity documented in preclinical research. Clinical trial documentation is available through ClinicalTrials.gov NCT07505745.

Earlier CohBar trial context

Earlier clinical development explored CB4211, a MOTS-c analog developed by CohBar. The CB4211 Phase 1a/1b trial (NCT03998514) in healthy non-obese volunteers and NAFLD subjects was completed but did not advance to broader Phase 2 development at that time. The current NCT07505745 trial investigating unmodified MOTS-c represents the more recent renewed clinical interest in the compound itself rather than analogs.

What this means for research applications

The current clinical development stage — one active Phase 2a trial with limited earlier human data — positions MOTS-c primarily as a research-stage compound. Research designs benefit from the compound's expanding preclinical evidence base and the emerging clinical data, but should not treat MOTS-c as a clinically validated therapeutic. This distinguishes it from compounds like Tesamorelin (FDA-approved) or even Retatrutide (Phase 3 with strong efficacy data).

Current Research Applications

Three research application categories account for most MOTS-c research use in Canadian laboratories — mitochondrial biology and bioenergetics, metabolic research (particularly glucose metabolism and insulin sensitivity), and aging research (particularly the age-related decline hypothesis). The compound's mechanism supports all three application categories through different aspects of its biological activity.

Mitochondrial biology and bioenergetics

Research designs investigating mitochondrial function benefit from MOTS-c's unique position as a mitochondrial-derived peptide. The compound is used to study mitochondrial-nuclear retrograde signaling, mitochondrial biogenesis in response to AMPK activation, and mitochondrial respiration efficiency in various disease models. The 2025 Auckland study on MOTS-c restoration of mitochondrial respiration in T2D hearts exemplifies this research direction.

Metabolic research

MOTS-c has documented effects on skeletal muscle glucose metabolism, insulin sensitivity, and fatty acid oxidation — all mediated through AMPK activation. Rodent studies of high-fat-diet-induced obesity and type 2 diabetes models have consistently reported metabolic improvements following MOTS-c administration. The current Phase 2a prediabetes trial represents the clinical extension of this preclinical research direction.

Aging and longevity research

The age-related decline of MOTS-c plasma levels, combined with its role as an AMPK activator and exercise mimetic, has driven substantial aging research interest. Research designs investigate whether MOTS-c replenishment addresses age-related metabolic decline, whether the compound extends healthspan markers in animal models, and how MOTS-c signaling interacts with other longevity pathways (NAD+/sirtuin biology, mTOR, IGF-1 axis).

Exercise physiology research

MOTS-c is naturally upregulated during exercise, making it a research tool for investigating exercise adaptation biology. Research designs use MOTS-c to probe how exercise-induced mitochondrial signaling adaptations occur, how exercise-mimetic pharmacology compares to actual exercise, and how age-related declines in exercise capacity relate to declining MOTS-c levels.

How MOTS-c Compares to Other Research Peptides

MOTS-c occupies a research niche distinct from most other research peptides because of its mitochondrial encoding origin, its AMPK activation mechanism, and its position at the intersection of mitochondrial and metabolic biology. Understanding how it compares to alternatives clarifies when MOTS-c is the appropriate research tool.

vs SS-31

Both MOTS-c and SS-31 target mitochondrial biology, but through fundamentally different mechanisms. MOTS-c is a signaling peptide that activates AMPK and translocates to the nucleus — its value is in mitochondrial-nuclear communication research. SS-31 is a structural peptide that binds cardiolipin on the inner mitochondrial membrane to stabilize cristae structure — its value is in mitochondrial structural integrity research. Research designs frequently use both in parallel to address signaling and structural aspects of mitochondrial biology simultaneously.

vs NAD+

MOTS-c and NAD+ both address cellular energy metabolism but through different molecular mechanisms. NAD+ is a coenzyme central to sirtuin activity, PARP-mediated DNA repair, and redox cycling. MOTS-c is a peptide signal that activates AMPK. Both decline with age, and research designs investigating age-related metabolic decline often use both compounds to probe different aspects of the cellular energy sensing network.

vs metabolic receptor agonists like Retatrutide

MOTS-c and Retatrutide operate at completely different biological levels. Retatrutide is a triple hormone receptor agonist that engages incretin biology through cell-surface receptors. MOTS-c operates inside cells, at the mitochondrial-nuclear communication level. Research designs comparing systemic hormone-mediated vs cellular bioenergetic mechanisms of metabolic regulation use both compounds as complementary tools rather than substitutes.

For a broader comparison of MOTS-c in metabolic research contexts, see Best Peptides for Weight Loss Research: A Comparison Guide for Canadian Labs.

Sourcing Considerations

Research-grade MOTS-c should meet four sourcing criteria: ≥99% HPLC purity, mass spectrometry identity confirmation, batch-specific certificates of analysis, and Canadian domestic supply chain integrity. The compound's 16-amino-acid length makes it relatively straightforward to synthesize, but variance in supplier quality remains substantial.

Verified HPLC purity. ≥99% high-performance liquid chromatography is the research standard. For MOTS-c specifically, the compound's synthesis is more forgiving than longer peptides, but batch documentation should still confirm purity for each vial received.

Mass spectrometry identity confirmation. MOTS-c has a specific molecular weight signature (approximately 2,174 Da for the 16-amino-acid peptide) that MS analysis can confirm. Suppliers who cannot provide MS-verified identity documentation introduce unnecessary compound identity risk.

Batch-specific certificates of analysis. Generic COAs that don't reference specific batch numbers are inadequate for research applications requiring documentation. Reliable suppliers provide COAs traceable to specific manufacturing lots.

Canadian domestic supply chain. Cross-border shipments of lyophilized peptides accumulate temperature variations and customs delays that domestic sourcing avoids. For a broader guide to evaluating research peptide suppliers, see Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers. Our Longevity & Mitochondrial Collection covers MOTS-c alongside other research peptides in the mitochondrial category.

Frequently Asked Questions

What is MOTS-c used for in research?

MOTS-c is used primarily in three research application categories: mitochondrial biology research (where the compound's unique mitochondrial encoding origin makes it valuable for studying mitochondrial-nuclear communication and signaling), metabolic research (particularly investigations of glucose metabolism, insulin sensitivity, and AMPK-mediated cellular energy regulation), and aging research (where the compound's documented age-related plasma decline supports research on age-associated bioactive peptide decline). The compound is not approved for human therapeutic use — the current Phase 2a trial (NCT07505745) represents the first substantial human clinical investigation.

Where is MOTS-c encoded?

MOTS-c is encoded within the 12S rRNA region of mitochondrial DNA — specifically within the MT-RNR1 gene. This mitochondrial encoding is what distinguishes MOTS-c from nearly every other research peptide, which are encoded by nuclear DNA. The compound belongs to a small class called mitochondrial-derived peptides (MDPs), which includes humanin (identified in 2001) and MOTS-c (identified in 2015 by Changhan Lee's laboratory at USC), plus smaller humanin-like peptides characterized more recently.

How does MOTS-c work mechanistically?

MOTS-c activates AMPK (the master cellular energy-sensing kinase) through an indirect pathway. It disrupts de novo purine synthesis in the folate cycle, causing accumulation of AICAR — an intermediate that also functions as an AMP mimetic and AMPK activator. When AICAR accumulates, AMPK activation follows. Beyond AMPK activation, MOTS-c also translocates from mitochondria to the nucleus under metabolic stress, where it directly regulates nuclear gene expression. This dual mechanism (AMPK activation + nuclear gene regulation) distinguishes MOTS-c from compounds that engage only one signaling pathway.

Why is MOTS-c called an exercise mimetic?

MOTS-c is naturally upregulated during physical exercise, and it activates the same AMPK signaling pathway that exercise activates through different upstream mechanisms. This dual characteristic — endogenous exercise-induced upregulation plus AMPK activation — leads researchers to describe MOTS-c as an "exercise mimetic." Research designs investigating whether pharmacological AMPK activation can produce exercise-like metabolic adaptations frequently use MOTS-c to probe this hypothesis.

Is MOTS-c approved for human use?

No. MOTS-c is not FDA approved for any human therapeutic use as of mid-2026. There is no active Investigational New Drug (IND) application for MOTS-c as a therapeutic. The current Phase 2a trial (NCT07505745) in prediabetes patients represents the first substantial human clinical investigation of MOTS-c itself. Research-grade MOTS-c is supplied strictly for laboratory research applications, not for human consumption. Research peptide suppliers do not sell MOTS-c for therapeutic purposes.

Where can researchers buy MOTS-c in Canada?

Research-grade MOTS-c is available through Canadian research peptide suppliers who meet HPLC purity, mass spectrometry identity, and batch documentation standards. Our MOTS-c research peptide is supplied at ≥99% HPLC purity with MS-verified identity, batch-specific COAs, and fast domestic Canadian shipping. All vials are sold strictly for laboratory research use only.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.